Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males.

Krug AW, Stelzner L, Rao AD, Lichtman AH, Williams GH, Adler GK.

Metabolism. 2013 Mar;62(3):386-91. doi: 10.1016/j.metabol.2012.08.011.

2.

Mineralocorticoid Receptor Blockade Improves Insulin Sensitivity in the Rat Heart and a Possible Molecular Mechanism.

Wang M, Li Y, Zhou K, Zhang G, Wang Y, Liu T, Zhang Y, Guo A, An Y.

Cell Physiol Biochem. 2016;39(3):860-70. doi: 10.1159/000447796.

3.

The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker.

Gamliel-Lazarovich A, Raz-Pasteur A, Coleman R, Keidar S.

Eur J Gastroenterol Hepatol. 2013 Sep;25(9):1086-92. doi: 10.1097/MEG.0b013e328360554a.

PMID:
23524523
4.

Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults.

Hwang MH, Yoo JK, Luttrell M, Kim HK, Meade TH, English M, Talcott S, Jaffe IZ, Christou DD.

Exp Gerontol. 2016 Jan;73:86-94. doi: 10.1016/j.exger.2015.11.017.

5.

Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet.

Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M, Koya D, Tsuneki H, Sasaoka T.

Endocrinology. 2010 May;151(5):2040-9. doi: 10.1210/en.2009-0869.

PMID:
20211973
6.

Cooperative Role of Mineralocorticoid Receptor and Caveolin-1 in Regulating the Vascular Response to Low Nitric Oxide-High Angiotensin II-Induced Cardiovascular Injury.

Pojoga LH, Yao TM, Opsasnick LA, Siddiqui WT, Reslan OM, Adler GK, Williams GH, Khalil RA.

J Pharmacol Exp Ther. 2015 Oct;355(1):32-47. doi: 10.1124/jpet.115.226043.

7.

Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.

Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ, Noma T, Kohno M, Nishiyama A, Nakano D.

Am J Physiol Renal Physiol. 2009 Sep;297(3):F802-8. doi: 10.1152/ajprenal.00197.2009.

8.

Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.

Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, Ishikawa H, Mizuno M, Sada T.

Eur J Pharmacol. 2015 Aug 15;761:226-34. doi: 10.1016/j.ejphar.2015.06.015.

PMID:
26073023
9.

The effect of α-cyclodextrin on postprandial lipid and glycemic responses to a fat-containing meal.

Jarosz PA, Fletcher E, Elserafy E, Artiss JD, Jen KL.

Metabolism. 2013 Oct;62(10):1443-7. doi: 10.1016/j.metabol.2013.05.015.

PMID:
23806736
10.

Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.

Łabuzek K, Liber S, Bułdak Ł, Krupej-Kędzierska J, Machnik G, Bobrzyk M, Okopień B.

Eur J Pharmacol. 2014 Mar 5;726:96-108.

PMID:
24486397
11.

Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice.

Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T, Shimomura I.

Cardiovasc Res. 2009 Oct 1;84(1):164-72. doi: 10.1093/cvr/cvp191.

PMID:
19505930
12.

Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.

Ramírez E, Klett-Mingo M, Ares-Carrasco S, Picatoste B, Ferrarini A, Rupérez FJ, Caro-Vadillo A, Barbas C, Egido J, Tuñón J, Lorenzo Ó.

Cardiovasc Diabetol. 2013 Nov 21;12:172. doi: 10.1186/1475-2840-12-172.

13.

Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome.

Hwang MH, Yoo JK, Luttrell M, Meade TH, English M, Christou DD.

Metab Syndr Relat Disord. 2015 Oct;13(8):356-61. doi: 10.1089/met.2015.0044.

14.

Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.

Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C.

Int J Cardiol. 2015 Dec 1;200:25-9. doi: 10.1016/j.ijcard.2015.05.127. Review.

PMID:
26404748
15.

Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.

Rogerson FM, Yao Y, Smith BJ, Fuller PJ.

Clin Exp Pharmacol Physiol. 2004 Oct;31(10):704-9.

PMID:
15554912
16.

Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.

Moore TD, Nawarskas JJ, Anderson JR.

Heart Dis. 2003 Sep-Oct;5(5):354-63. Review.

PMID:
14503934
17.

Role of mineralocorticoid receptors in arterial stiffness in human aging.

Hwang MH, Yoo JK, Luttrell M, Kim HK, Meade TH, English M, Nichols WW, Christou DD.

Exp Gerontol. 2013 Aug;48(8):701-4. doi: 10.1016/j.exger.2013.05.058.

18.

Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation.

Wei Y, Whaley-Connell AT, Habibi J, Rehmer J, Rehmer N, Patel K, Hayden M, DeMarco V, Ferrario CM, Ibdah JA, Sowers JR.

Hypertension. 2009 Feb;53(2):158-65. doi: 10.1161/HYPERTENSIONAHA.108.121954.

19.

Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.

Hu X, Li S, McMahon EG, Lala DS, Rudolph AE.

Mini Rev Med Chem. 2005 Aug;5(8):709-18. Review.

PMID:
16101407
20.

Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.

Yasuoka S, Kai H, Kajimoto H, Kudo H, Takayama N, Anegawa T, Koga M, Miyamoto T, Mifune H, Kage M, Hirooka Y, Imaizumi T.

Circ J. 2013;77(6):1474-81.

Items per page

Supplemental Content

Support Center